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Abstract 
Diabetes Miletus (DM) is a global epidemic disease. It is estimated that there are already 415 million adults aged 20–
79 years diabetics worldwide. Sildenafil citrate is a phosphodiesterase type 5 (PDE5) inhibitor, which increases cyclic 
guanosine monophosphate (cGMP) and metformin (MET) is a biguanide used for the treatment of type 2 diabetes which 
increases peripheral insulin sensitivity. Aim: This study aims to assess the effect of sildenafil citrate and metformin on 
lipid profile and glycemic control in diabetic and prediabetic albino rats. Materials and methods: Adult male albino 
rats are used and divided into nine groups each group consists of 10 rats, diabetes is induced by feeding a high-fat 
diet (HFD) for an initial period of 2 weeks followed by a single intraperitoneal injection of (35 mg/kg) Streptozotocin. 
Prediabetes is induced by feeding (HFD) and glucose in water for a period of 2 weeks. Sildenafil was given in a dose of (5 
&10 mg/kg/day orally for 4 weeks), metformin was given in a dose of (50 &100 mg/kg/day orally for 4 weeks) using oral 
gavages to normal healthy rats, diabetic and prediabetic rats. Blood samples were collected after 4 weeks of treatment 
in all experimental groups. Results: Combined administration of sildenafil and metformin on diabetic rats improving 
hyperglycemia, oxidative stress, and hyperlipidemia induced by streptozotocin than the administration of metformin 
or sildenafil alone. Conclusion: Sildenafil has beneficial effects against some diabetic complications. The present study 
showed that sildenafil with metformin has beneficial effects against diabetic complications.
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IntroductIon
Diabetes Meletus (DM) is worldwide epidemic disease. It is estimated that there are about 415 million adults aged 
20–79 with diabetes, including 193 million who 
are undiagnosed[1]. A further 318 million adults 
have impaired glucose tolerance, which puts 
them at high risk of developing the disease. By 
the end of 2015, If this high rate not stopped, by 
2040 there will be 642 million people living with 
the disease [2]. It is estimated that 5%–10% of 
diagnosed cases are of Type I diabetes mellitus 
(DM), while the remaining 90%–95% are of Type 
II DM [3, 4]. 
Erectile dysfunction (ED) is defined as the 
persistent inability to attain and maintain an 
erection sufficient to permit satisfactory sexual 
activity and is a common complication of DM 
in men [4]. The prevalence of ED of any degree 
in men aged 40–70 years was predestined to be 
52%. ED occurs at an earlier age in men with 
DM than in men in the general population [5]. 
ED in diabetes is often complex and caused by 
several mechanisms including vascular disease, 
autonomic neuropathy, hormonal imbalance, 
and psychogenic factors. The risk of ED increases 
with duration of diabetes and is directly related to 
poor glycemic control and the presence of other 
risk factors such as hypertension, smoking, and 
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hyperlipidemia [4].
Treatment options for ED include psychological 
management, vacuum constriction devices, 
intracavernosal injections, transurethral drug 
delivery, penile prostheses, vascular surgery, 
and modification of medication contributing 
to the problem [6]. However, many of these 
treatments have limited acceptability to users 
[7]. The ideal goal in the treatment of ED is 
restoration of erectile capacity using a minimally 
invasive and safe treatment [8]. Sildenafil is the 
first oral drug to be marketed specifically for the 
treatment of ED [4]. Sildenafil has the potential 
to enhance erectile activity under conditions 
of sexual stimulation. It does not have a direct 
effect on libido or smooth muscle [6]. 
The use of Sildenafil in patients with DM in highly 
increased and its effect on glycated hemoglobin 
and fasting plasma glucose are still inconclusive 
[9]. 
This study is an attempt to assess the effect of 
daily oral sildenafil citrate on lipid profile and 
glycemic control in diabetic and prediabetic rats 
with metabolic syndrome, whether Sildenafil 
might represent new therapeutic approaches for 
preventing and treating metabolic syndrome.
MaterIal and Methdos
This work was done at faculty of medicine, Al-
Azhar University (Assiut branch), pharmacology 
department.
Experimental animals:  Ninety adult male albino 
rats were chosen as an animal model for this 
study with initial body weight (BW) ranging from 
160-180 g.  Rats were purchased from animal 
house, Faculty of Medicine, Assiut University, 
Assiut, Egypt, and were maintained on standard 
diet of known composition, and water supply 
freely in clean containers. They were kept for 
two weeks to adapt to the laboratory conditions 
before the start of the experiment. The animals 
were housed in standard polypropylene cages 
with stainless steel good, aerated covers and 
maintained under controlled room temperature 
with 12 hrs light-dark cycle.  
Induction of diabetes: Type 2 DM was induced by 
feeding a high fat diet (HFD) for 2 weeks followed 
by an intraperitoneal injection of 35 mg/kg b.wt 
streptozotocin dissolved in citrate buffer pH 4.5 
[10] . After that, the rats were kept for next 48 
hours on oral 10% glucose solution on top of 
their chaw to prevent hypoglycemia [11]. After 
Seven days the blood glucose levels for injected 
rats were measured. Rats having blood glucose 
level ≥ 200 mg/dl, after 2 hours of glucose intake 
were considered diabetic [10].
Induction of prediabetes: Prediabetes in rats 
were induced by feeding a high fat diet (HFD) 
(45% energy from fat) and glucose in water for 
period of 2 weeks. Development of prediabetes 
was confirmed by development of obesity, 
hyperinsulinemia, and insulin resistance and 
not frank hyperglycemia or DM, in these cases 
the rats considered prediabetic [12] .
 Experimental design: The experimental animal 
was divided into nine groups, each group 
comprising ten rats designated as follows: 
G1: Normal control rats. 
G2: Diabetic control rats. 
G3: Diabetic rats treated with 
metformin100mg/kg b.wt orally for 4 weeks. 
G4: Diabetic rats treated with Sildenafil 
citrate10 mg/kg b.wt orally for 4 weeks. 
G5: Diabetic rats treated with Sildenafil citrate 
10 mg/kg b.wt and metformin 100mg/kg b.wt 
orally for 4 weeks. 
G6: Prediabetic control rats. 
G7: Prediabetic rats treated with metformin 50 
mg/kg b.wt orally for 4 weeks. 
G8: Prediabetic rats treated with Sildenafil 
citrate 5 mg/kg b.wt orally for 4 weeks. 
G9: Prediabetic rats treated with Sildenafil 
citrate 5 mg/kg b.wt and metformin 50mg/kg 
b.wt orally for 4 weeks.
Collection of samples for analysis: At the end of 
the 6th week, food was withdrawn from the rats 
and they were fasted for 8 h, but had free access 
to water, and then anesthetized with thiopental 
(40 mg/kg ip) [13]. Blood samples were collected 
from orbital venous plexus in non-heparinized 
tubes. Blood samples were centrifuged at 2500 
rpm for 15 min, and the clear samples of blood 
serum were separated and stored at -80oC 
until used for the measurement of the levels of 
blood glucose (BG) level (mg/dl), insulin level 
(pmol/L), total cholesterol (TC) (mg/dl), LDL-
cholesterol (mg/dl), HDL-cholesterol (mg/dl) 
and triglycerides (TG) (mg/dl).
Biochemical studies: Serum glucose level was 
measured by glucose oxidase method using 
Blood glucose (BG) kit (Egyptian Company for 
Biotechnology-Egypt) [14]. 
Insulin estimated using enzyme linked 
immunosorbent assay ELISA methods using 
Insulin kit (Sigma-Aldrich Co. LLC-USA)  [15]. 
Serum cholesterol level was done by enzymatic 
–colometric test with lipid clearing factor) using 
Serum cholesterol kit (Egyptian company for 
biotechnology-Egypt) [16]. Serum triglycerides 
were estimated by an enzymatic colorimetric test 
with GPO-PAP method using Serum triglycerides 
kit (Egyptian Company for Biotechnology-Egypt) 
[17]. Serum high density lipoprotein (HDL) was 
estimated by enzymatic colorimetric method 
Using Serum high density lipoprotein (HDL) kit 
(Egyptian Company for Biotechnology-Egypt) 
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[17].The serum LDL-cholesterol was estimated 
according to using the following equation; 
LDL-cholesterol in mg/dl= Total cholesterol – 
Triglyceride/5-HDL-cholesterol [17].
Statistical analysis: The obtained data were 
subjected to analysis of variance according to the 
procedures out lined by Snedecor and Cochran. 
The mean values were compared according 
to Duncan’s multiple range test (DMRT) [18]. 
The data were analysed using Co Stat software 
for windows (version 6.3), (Co Hort Software, 
Monterey, Calif).   
results
Changes of BW, BG, and insulin level among 
different groups.
A-In diabetic groups:  The obtained data showed 
a significant (p<0.01) increase of body weight in 
G4 than diabetic control group with no significant 
(P>0.05) change between G3, G5 and diabetic 
control group as shown in table (1) and figure 
(1). The BG level showed a significant (p<0.01) 
lower level in all diabetic treated groups than 
control diabetic group with significant (p<0.01) 
lower level of G5 than G4 and G3 groups as 
shown in table (1).There was significant (p<0.01) 
increase of serum insulin level in G4 and G5 
than diabetic control group with no significant 
(P>0.05) change between G3 and diabetic control 
group as shown in table 1. 
Table 1. Changes of body weight, blood glucose 
and insulin level among different groups.
Gr B w (g) BG (mg/dl) Insulin(IU/dl)
G1 170.2c±12.7 89.3d ±12.5 12.7c±2.2
G2 134e±15.59 230a ±35.8 4.17e±0.4
G3 131.8e±12.6 119.7b±14.3 4.87e±0.9
G4 155.2d±8.7 124.2b±16.3 10.1d ±1.1
G5 137.3e ±12.8 110.2c±7.3 10.6d±0.8
G6 197.3a±10.4 110.7c±8.6 15.2b±2.9
G7 178.3b±10.6 98.7d±11.1 15.92b±2.6
G8 201.8a±10.7 98.5d±7.7 25.1a±2.85
G9 194.3ab±7.2 91.3d±5.5 25.3a ±3.6
F 117.65** 180.2 ** 282.4**
P. 0.00 0.00 0.00
Where G1: Control untreated; G2: Diabetic 
untreated rats; G3: Diabetic rats treated with 
metformin rats; G4: Diabetic  rats  treated with 
Sildenafil citrate; G5:Diabetic  rats  treated with 
Sildenafil citrate & metformin; G6: Prediabetic 
untreated rats; G7: Prediabetic rats treated with 
metformin; G8:Prediabetic  rats  treated with 
Sildenafil citrate; G9: Preiabetic  rats  treated 
with  Sildenafil citrate & metformin.
** indicate P < 0.01. Means followed by a same 
letter are not significantly different at the 1% 
level by DMRT.F: F -test, P: p-value 
-letter (a) refer to highest mean and letter (b) 
referred to subsequent lower mean and so on.
Comparison between body weight percentages 
in all groups.
B-In prediabetic groups: The obtained data 
showed a significant (p<0.01) reduction of body 
weight in G7 than prediabetic control group with 
no significant (P>0.05) change between G8, G9 
and prediabetic control group as shown in table 
(1). There was significant (p<0.01) lower level 
in Serum blood glucose level in all prediabetic 
treated groups than prediabetic control group 
with no significant (P>0.05) difference between 
all treated groups as shown in table (1). The 
serum insulin level showed a significant (p<0.01) 
increase in G8 and G9 than prediabetic control 
group with no significant (P>0.05) change 
between G7 and prediabetic control group as 
shown in table 1.
The obtained data from fig (1-A) showed that 
in G3 body weight decreased by 2% but in G4 
and G5 body weight increased by 16% and 3% 
respectively. The fig (1-D) showed that G3, G4 
and G5 glucose level decreased by 48%, 46% and 
52% respectively. Fig (1-E) showed that G3, G4 
and G5 serum insulin level increased by 17%, 
142% and 154% respectively.
B-In prediabetic groups: The control prediabetic 
group value was calculated a 100% to compare 
between it and all treated groups. 
The obtained data from fig (1-B) showed that 
G7 and G9 body weight decreased by 10% and 
2% but in G8 body weight increased by 2% 
respectively. Data from fig (1-E) showed that G7, 
G8 and G9 glucose level decreased by 11%, 11% 
and 17% respectively. Fig (1-F) showed that G7, 
G8 and G9 serum insulin level increased by 5%, 
65% and 67% respectively.
Changes of serum cholesterol, triglycerides, HDL 
and LDL level among different groups.
A-In diabetic groups: The obtained data showed 
a significant (p<0.01) lower level in Serum 
cholesterol in all diabetic treated groups than 
control diabetic group with significant (p<0.01) 
lower level of G5 than G3 and G4 groups as 
shown in table (2). There was a significant 
(p<0.01) lower level in Serum triglycerides in 
all diabetic treated groups than control diabetic 
group with significant (p<0.01) lower level of G5 
than G3 and G4 groups as shown in table (2). 
Serum HDL was significantly (p<0.01) increased 
in all diabetic treated groups than control 
diabetic group with significant (p<0.01) increase 
level of G5 than G3 and G4 groups as shown in 
table (2). The obtained data showed a significant 
(p<0.01) lower level in Serum LDL in all diabetic 
treated groups than control diabetic group with 
significant (p<0.01) lower level of G5 than G3 
and G4 groups as shown in table 2.
Ahmed El-Sayed et al. Effect of sildenafil citrate on prediabetic and diabetic rats 
Int. J. Curr. Res. Physiol. Pharmacol. 2021;5(1):4-13 7
Table 2. Changes of serum cholesterol, 








G1 66h±2.8 50.5h±3.7 37a±2.8 20i±2.8
G2 187.7a±6 141.8a±4.6 22f±2.8 139a±5.2
G3 88.8d±3 70.8e±2.9 30.17d± 76.1c±4.3
G4 93.5c±3.7 98.3c±4.3 29.3d±3.5 47.3e±5.9
G5 81.3e±4.3 65.2f±2.9 34b±2.8 40.3f±4.1
G6 117.8b±6 115.3b±4.3 25.8e±2.9 81b±6.9
G7 74.5g±3.7 64.5f±3.7 32c±2.8 53.3d±4.3
G8 78.2f±5.7 74.2d±5.3 30.6cd±2.4 36.2g±6.4
G9 68.2h±5.7 55.83g±4.6 34.8b±2.9 30.8h±4.6
F 1585** 1303.7** 60.6** 1223.5**
P. 0.00 0.00 0.00 0.00
Where G1: Control untreated; G2: Diabetic 
untreated rats; G3: Diabetic rats treated with 
metformin rats; G4: Diabetic rats treated with 
Sildenafil citrate; G5:Diabetic  rats  treated with 
Sildenafil citrate & metformin; G6: Prediabetic 
untreated rats; G7: Prediabetic  rats  treated 
with metformin; G8:Prediabetic  rats  treated 
with  Sildenafil citrate; G9: Prediabetics  rats 
treated with  Sildenafil citrate & metformin.
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** indicate P < 0.01. Means followed by a same 
letter are not significantly different at the 1% 
level by DMRT.
-letter (a) refer to highest mean and letter (b) 
referred to subsequent lower mean and so on.
B-In prediabetic groups: The obtained data 
showed a significant (p<0.01) lower level in 
Serum cholesterol in all prediabetic treated 
groups than control prediabetic group with 
significant (p<0.01) lower level of G9 than G7 
and G8 groups as shown in table (2). There 
was significant (p<0.01) lower level in Serum 
triglycerides in all prediabetic treated groups 
than control prediabetic group with significant 
(p<0.01) lower level of G9 than G7 and G8 groups 
as shown in table (2). The HDL level showed a 
significant (p<0.01) increase in all prediabetic 
treated groups than control prediabetic group 
with significant (p<0.01) increase level of G9 
than G7 and G8 groups as shown in table (2). 
The obtained data showed a significant (p<0.01) 
lower level in Serum LDL in all prediabetic 
treated groups than control prediabetic group 
with significant (p<0.01) lower level of G9 than 
G7 and G8 groups as shown in table 2. 
Comparison between serum cholesterol, 
triglycerides, HDL and LDL level among different 
groups.
A-In diabetic groups: The control diabetic group 
value was calculated a 100% to compare between 
it and all treated groups. 
The obtained data from fig (2-B) showed that G3, 
G4 and G5 serum cholesterol level decreased by 
53%, 50% and 57% respectively. Fig (2-D) showed 
that G3, G4 and G5 serum triglycerides level 
decreased by 50%, 31% and 54% respectively. 
Serum HDL showed that G3, G4 and G5 level 
increased by 37%, 33% and 55% respectively 
fig (2-F). There was decreased in serum LDL 
level in G3, G4 and G5 by 45%, 66% and 71% 
respectively as shown in fig (2-H).
B-In prediabetic groups: The control prediabetic 
group value was calculated a 100% to compare 
between it and all treated groups. Fig (2-A) 
showed that G7, G8 and G9 serum cholesterol 
level decreased by 37%, 34% and 42% 
respectively. Serum triglycerides level in G7, 
G8 and G9 decreased by 44%, 36% and 52% 
respectively Fig (2-D).
The obtained data from fig (2-E) also showed 
that G7, G8 and G9 serum HDL level increased 
by 24%, 19% and 35% respectively and serum 
LDL level in G7, G8 and G9 decreased by 34%, 
55% and 62% respectively as shown in fig (2-G).
dIscussIon
The results present study showed that 
administration of sildenafil citrate to prediabetic 
and diabetic albino rats treated with metformin 
has no significant changes on BW. The BW of 
diabetic rats treated with metformin by decreased 
by 2% and in diabetic rats treated with Sildenafil 
citrate and (Sildenafil citrate & metformin) 
by 16% and 3% respectively in comparison 
with diabetic untreated rats as shown in fig 
(1). Body weight decreased by 10% and 2% in 
prediabetic rats treated with metformin and 
(Sildenafil citrate& metformin) but in prediabetic 
rats treated with Sildenafil citrate body weight 
increased by 2% respectively in comparison 
with prediabetic untreated rats as shown in fig 
(1). In the diabetic and prediabetic rats treated 
with metformin, the results of our work are in 
agreement with the results obtained by Mogul 
et al., 2003 [19] and Mamikutty et al [4] who 
reported that weight loss in obese women who 
were treated by metformin for 6 months was 
5%. In the diabetic and prediabetic rats treated 
with Sildenafil citrate, the results of our work 
agree with the results obtained by Johann et al. 
& Dilworth et al. & Nisoli et al. who found that 
there is no effect of Sildenafil citrate on body 
weight [8, 20, 21]. 
In the diabetic and prediabetic rats treated with 
metformin and sildenafil, there is no significant 
change (P< 0.05) on body weight in comparison 
with control diabetic and prediabetic rats. Our 
results are in agreement with Bruckbauer et 
al. who reported that combination of metformin 
and sildenafil did not change body weight 
[22]. Tran and Howes  found that Sildenafil 
citrate did not give any change in body weight 
of STZ diabetic induced rats and Chronic 
phosphodiesterase(PDE)-5 inhibitors lead to 
increase energy expenditure, that improve 
energy balance and body weight reduction that 
may enhance insulin action [23].
To explain this, it should be noted that 
increasing cGMP is a fundamental mechanism 
of action of sildenafil citrate [24]. A study on 
rat hepatocytes cGMP indicated that sildenafil 
citrate increases hepatocytes in vitro level but 
does not significantly alter glycogenolysis and 
gluconeogenesis [25]. Nitric oxide has been 
suggested as a second messenger molecule for 
the stimulatory effect of insulin in carbohydrate 
metabolism [26].
Mitschke et al. found that, chronic treatment 
(12 weeks) with the PDE-5 inhibitor sildenafil 
improved insulin sensitivity [27]. Lizhi, reported 
that PDE 5-inhibitors, lead to increase SIRT1 
signaling in mice that lead to increase energy 
expenditure in skeletal muscle cells, improve 
energy balance and increase insulin action in 
both diet-induced obese, insulin resistant mice 
and diabetic patients [28].
The effect on serum glucose level and serum 
insulin level: The results present study showed 
that showed that the blood glucose level 
decreased in diabetic rats treated with Sildenafil 
citrate, metformin and (Sildenafil citrate & 
metformin) by 48%, 46% and 52% respectively 
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in comparison with diabetic untreated rats and 
serum insulin level increased by 17%, 142% and 
154% respectively in comparison with diabetic 
untreated rats.  In prediabetic groups there were 
no significant difference in serum blood glucose 
level of prediabetic groups as glucose level 
decreased by 11%, 11% and 17% respectively 
in comparison with diabetic untreated rats and 
serum insulin level increased by 5%, 65% and 
67% respectively in comparison with prediabetic 
untreated rats as shown in fig (1). The result of 
the current study is in agreement with results 
of Ayala et al. who found that chronic inhibition 
of PDE-5 enhance insulin action in obese rats, 
which may explained by PDE-5 inhibition may 
improve insulin action and prevent endothelial 
dysfunction [29]. There is evidence supports 
the insulin resistance and type 2 diabetes 
may cussed by endothelial dysfunction [30]. 
Also endothelial dysfunction lead to impairing 
glucose uptake by muscles is by a decreasing 
the NO levels and cGMP production [31]. Thus, 
preventing a decrease in cGMP levels, resulting 
in improved insulin action and glucose uptake 
by muscles. This effect may be related to central 
nervous system as sildenafil has been found 
to cross the blood brain barrier, and PDE-5 
expression has been detected in the brain [32].
Thus, signaling through cGMP in the central 
nervous system may play a role in the regulation 
of insulin action and energy homeostasis as 
stated by Ayala et al [29]. 
 Hill et al observed a significant improvement in 
insulin sensitivity in the severely obese subjects 
and they suggests that this is a class effect of 
PDE5 inhibitors [33].
Also, these findings are agreement with El Sayed 
et al who found that sildenafil citrate elevated 
serum insulin and decreased blood glucose level 
in dose dependent manner and they explained it 
by Inhibition of cGMP hydrolysis that activates 
cGMP-dependent protein kinase G, which 
phosphorylates and activates hormone-sensitive 
lipase then increases free fatty acid (FFA) 
availability and energy expenditure [34]. 
 The results of this study disagree with the 
results obtained by other workers they showed 
that sildenafil citrate has in significant effect in 
reducing the blood glucose level of diabetic rats 
[35-37].
The results of this study showed that, 
combination of metformin and sildenafil has 
more significant reduction (P< 0.01) on serum 
blood glucose of the diabetic rats more than 
metformin alone or sildenafil alone but there 
is no significant (P< 0.05) difference on serum 
blood glucose in the prediabetic treated rats in 
comparison with control prediabetic rats. Also, 
combination of metformin and sildenafil has 
more significant increase (P< 0.01) on serum 
insulin level of the diabetic and prediabetic 
rats more than metformin alone but there is no 
significant (P< 0.05) difference on serum insulin 
level between combination and sildenafil alone.
In patients with DM2, an increase in free 
radicals caused by various risk factors (such 
as dyslipidemia, obesity and hyperglycemia) 
might enable the oxidative stress that reduces 
production and availability of NO with the 
subsequent appearance of ED [38].
Inhibitors of PDE-5, such as sildenafil, require 
adequate levels of NO to be effective. Because IR 
states have decreased levels of NO and insulin-
sensitizing agents improve IR, we postulate that, 
in patients with ED and IR and a poor response 
to sildenafil, the addition of metformin can 
optimize the response to sildenafil, improving 
endothelial function.
We hypothesize that metformin and Sildenafil 
citrate improve endothelial function by reducing 
blood sugar levels, the present study also 
confirmed that metformin and Sildenafil citrate 
have a similar curative effect in reducing blood 
sugar levels, improving islet function and 
reducing the IR index. More ever, combination 
of metformin and seldinafil is more successful 
at improving endothelial function than Sildenafil 
citrate alone and metformin alone, the reason for 
which is currently unclear and requires further 
study.
The effect on lipid profile: the results of the 
present showed that, in diabetic rats treated 
with metformin, Sildenafil citrate and (Sildenafil 
citrate& metformin) serum cholesterol level 
decreased by 53%, 50% and 57% respectively in 
comparison with diabetic untreated rats, serum 
triglycerides level decreased by 50%, 31% and 
54% respectively in comparison with diabetic 
untreated rats, serum HDL level increased by 
37%, 33% and 55% respectively in comparison 
with diabetic untreated rats and serum LDL level 
decreased by 45%, 66% and 71% respectively 
in comparison with diabetic untreated rats as 
shown in fig (2). prediabetic rats treated with 
metformin, Sildenafil citrate and (Sildenafil 
citrate& metformin) serum cholesterol level 
decreased by 37%, 34% and 42% respectively 
in comparison with prediabetic untreated rats, 
serum triglycerides level decreased by 44%, 
36% and 52% respectively in comparison with 
prediabetic untreated rats, serum HDL level 
increased by 24%, 19% and 35% respectively in 
comparison with prediabetic untreated rats and 
serum LDL level decreased by 34%, 55% and 
62% respectively in comparison with diabetic 
untreated rats as shown in fig (2).
In the diabetic rats treated with Sildenafil citrate, 
our results agree with Mitschke et al. who stated 
that diabetic rats treated with Sildenafil citrate 
decreased significant of serum triglycerides, 
serum total cholesterol level and serum LDL 
level, while serum HDL level increased significant 
in comparison with diabetic untreated rats. 
This positive effect of sildenafil could be due to 
increased appearance of brown-like adipocytes 
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in white adipose tissue [27].
The significant decrease in the serum lipid levels 
in treated diabetic rat might have been due to the 
increase insulin sensitivity following sildenafil 
administration. 
There is an evidence that use of PDE-5 inhibitors 
could overcome the oxidative stress-induced 
cellular dysfunctions and apoptosis associated 
with lipid peroxidation derivatives by increasing 
cyclic nucleotides [39]. Polte and Schroder, 
reported an antioxidant property for NO donors 
in vascular endothelium through concerted 
action of cGMP and cAMP[9]. In addition, the 
hypolipidemic and insulin sensitizing effects 
of sildenafil may be attributed to its anti-
inflammatory effect [39]. It was shown that 
sildenafil promotes browning of white adipocytes 
in vitro [40].
In the prediabetic rats treated with Sildenafil 
citrate, our results are in agreement with Ayala 
et al. who stated that prediabetic rats treated 
with Sildenafil citrate decreased significant of 
serum triglycerides, serum total cholesterol 
level and serum LDL level, while serum HDL 
level increased significant in comparison with 
prediabetic untreated rats and this improving 
effect of sildenafil may be explained by its 
direct effects of on metabolism other than eNOS 
activation, Improving insulin function and 
increase lipoprotein lipase activity[29].
Bennani-Kabchi et al explained the significant 
decrease in plasma TAG to the increased rate of 
lipolysis that is mediated by increase of plasma 
lipase activity [41].
The results of this study showed that, combination 
of metformin and sildenafil has more significant 
reduction (P< 0.01) on serum cholesterol, 
triglycerides and LDL level of the diabetic and 
prediabetic rats more than metformin alone or 
sildenafil alone. Also, combination of metformin 
and sildenafil has more significant increase (P< 
0.01) on serum HDL level of the diabetic and 
prediabetic rats more than metformin alone and 
sildenafil alone.
Our results are in agreement with Lizhi, 
who investigate the Synergistic effect of 
Leucine-Metformin-Sildenafil on Nonalcoholic 
Steatohepatitis [28]. 
conclusIon
Findings of the present study indicate that 
sildenafil citrate exerts hypoglycemic effect 
on diabetic albino rats. In addition to its 
hypoglycemic effect, it also has hypolipidemic 
effect on both diabetic and prediabetic albino 
rats and these effects may be attributed to its 
anti-inflammatory effect. More ever, our study 
revealed that combination of Sildenafil citrate 
and Metformin have more effect in prevention 
and treatment of diabetes mellitus in albino rats 
than treatment by Sildenafil alone or Metformin 
alone. 
Further studies are required for further 
evaluation and establishment of the beneficial 
effects of sildenafil citrate in treatment and 
prevention of vascular and other complications 
of diabetes mellitus and mechanisms of actions.
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